Brandon Folkes
Stock Analyst at Rodman & Renshaw
(1.90)
# 3,065
Out of 4,761 analysts
47
Total ratings
29.41%
Success rate
-2.5%
Average return
Main Sectors:
Stocks Rated by Brandon Folkes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RMTI Rockwell Medical | Initiates: Buy | $5 | $1.77 | +182.49% | 1 | Nov 14, 2024 | |
| ACHV Achieve Life Sciences | Initiates: Buy | $12 | $3.17 | +278.55% | 1 | Nov 14, 2024 | |
| EPRX Eupraxia Pharmaceuticals | Initiates: Buy | $9 | $3.65 | +146.58% | 1 | Nov 14, 2024 | |
| OMER Omeros | Initiates: Buy | $9 | $9.18 | -1.96% | 2 | Nov 14, 2024 | |
| ADIL Adial Pharmaceuticals | Initiates: Buy | $8 | $0.79 | +917.81% | 1 | Nov 14, 2024 | |
| EBS Emergent BioSolutions | Reiterates: Buy | $16 | $7.71 | +107.52% | 6 | Sep 13, 2024 | |
| CRMD CorMedix | Initiates: Buy | $13 | $10.13 | +28.33% | 1 | Aug 26, 2024 | |
| MIST Milestone Pharmaceuticals | Initiates: Buy | $9 | $2.04 | +341.18% | 1 | Aug 22, 2024 | |
| MNKD MannKind | Initiates: Buy | $8 | $5.76 | +38.89% | 1 | Jun 13, 2024 | |
| TRVI Trevi Therapeutics | Initiates: Buy | $7 | $4.60 | +52.17% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $1.73 | +304.62% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $1.66 | +502.41% | 2 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $0.33 | +3,841.78% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $59 | $33.69 | +75.13% | 4 | Sep 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $180 | $136.01 | +32.34% | 2 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $22 | $0.57 | +3,741.45% | 3 | Dec 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $5.19 | +73.41% | 1 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $28 → $32 | $35.32 | -9.40% | 3 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22,000 | $4.76 | +462,084.87% | 1 | Aug 31, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $30 → $22 | $29.13 | -24.48% | 5 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $720 | $2.99 | +23,980.27% | 1 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $78 → $40 | $57.94 | -30.96% | 3 | May 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $405 → $315 | $5.77 | +5,359.27% | 3 | Mar 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $50 | $36.91 | +35.46% | 1 | Jul 12, 2018 |
Rockwell Medical
Nov 14, 2024
Initiates: Buy
Price Target: $5
Current: $1.77
Upside: +182.49%
Achieve Life Sciences
Nov 14, 2024
Initiates: Buy
Price Target: $12
Current: $3.17
Upside: +278.55%
Eupraxia Pharmaceuticals
Nov 14, 2024
Initiates: Buy
Price Target: $9
Current: $3.65
Upside: +146.58%
Omeros
Nov 14, 2024
Initiates: Buy
Price Target: $9
Current: $9.18
Upside: -1.96%
Adial Pharmaceuticals
Nov 14, 2024
Initiates: Buy
Price Target: $8
Current: $0.79
Upside: +917.81%
Emergent BioSolutions
Sep 13, 2024
Reiterates: Buy
Price Target: $16
Current: $7.71
Upside: +107.52%
CorMedix
Aug 26, 2024
Initiates: Buy
Price Target: $13
Current: $10.13
Upside: +28.33%
Milestone Pharmaceuticals
Aug 22, 2024
Initiates: Buy
Price Target: $9
Current: $2.04
Upside: +341.18%
MannKind
Jun 13, 2024
Initiates: Buy
Price Target: $8
Current: $5.76
Upside: +38.89%
Trevi Therapeutics
Jun 13, 2024
Initiates: Buy
Price Target: $7
Current: $4.60
Upside: +52.17%
Jun 13, 2024
Initiates: Buy
Price Target: $7
Current: $1.73
Upside: +304.62%
Jun 13, 2024
Initiates: Buy
Price Target: $10
Current: $1.66
Upside: +502.41%
Jun 13, 2024
Initiates: Buy
Price Target: $13
Current: $0.33
Upside: +3,841.78%
Sep 26, 2023
Reiterates: Overweight
Price Target: $59
Current: $33.69
Upside: +75.13%
Aug 22, 2023
Reiterates: Overweight
Price Target: $180
Current: $136.01
Upside: +32.34%
Dec 5, 2022
Maintains: Overweight
Price Target: $30 → $22
Current: $0.57
Upside: +3,741.45%
Feb 25, 2022
Initiates: Overweight
Price Target: $9
Current: $5.19
Upside: +73.41%
Jan 27, 2022
Upgrades: Overweight
Price Target: $28 → $32
Current: $35.32
Upside: -9.40%
Aug 31, 2021
Initiates: Overweight
Price Target: $22,000
Current: $4.76
Upside: +462,084.87%
Aug 6, 2021
Downgrades: Neutral
Price Target: $30 → $22
Current: $29.13
Upside: -24.48%
Jul 30, 2021
Initiates: Overweight
Price Target: $720
Current: $2.99
Upside: +23,980.27%
May 7, 2020
Downgrades: Neutral
Price Target: $78 → $40
Current: $57.94
Upside: -30.96%
Mar 5, 2020
Reiterates: Overweight
Price Target: $405 → $315
Current: $5.77
Upside: +5,359.27%
Jul 12, 2018
Maintains: Overweight
Price Target: $42 → $50
Current: $36.91
Upside: +35.46%